Johnson & Johnson reports icotrokinra arthritis benefit

Johnson & Johnson (JNJ) reported that Icotyde, a therapy co-marketed with Protagonist Therapeutics (PTGX), showed success in a late-stage trial for psoriatic arthritis, according to the company. The drug is already FDA-approved for plaque psoriasis. Up to 30% of plaque psoriasis patients also develop psoriatic arthritis, per studies.

Johnson & Johnson (JNJ) presented Phase 2 data on nipocalimab for Sjögren’s disease, showing high patient satisfaction and symptom improvement. The drug demonstrated a 50%+ improvement in salivary flow vs. placebo. JNJ is conducting Phase 3 trials, with FDA designations for fast-track development.

Johnson & Johnson reported that its once-daily pill, Icotyde, showed significant improvement in psoriatic arthritis symptoms in a late-stage trial. 58% of patients taking Icotyde saw a 20% improvement in joint counts and disease activity, compared to 41% on placebo. The drug is already FDA-approved for psoriasis and could expand into psoriatic arthritis, with peak sales expected to exceed $5 billion.

Johnson & Johnson's Phase 3 study of ICOTYDE for psoriatic arthritis showed 58% of patients achieved an ACR20 response at Week 16, with 57% clearing or nearly clearing skin lesions. The once-daily oral peptide demonstrated joint and skin improvements, according to data presented at the American College of Rheumatology Convergence. ICOTYDE is not yet approved for psoriatic arthritis treatment.

Johnson & Johnson (JNJ) presented new Phase 2 data on nipocalimab for Sjögren's disease, showing mouth dryness as the most critical symptom for patients. The study found a 50% increase in saliva production in more patients treated with nipocalimab compared to placebo. Two Phase 3 studies are ongoing, focusing on patient-valued outcomes. Nipocalimab has received Breakthrough Therapy and Fast Track Designations from the FDA for this indication.

Johnson & Johnson (JNJ) reported positive Phase 3 trial results for ICOTYDE (icotrokinra) in treating psoriatic arthritis. 58% of patients achieved ACR20 response vs. 41% on placebo. The drug showed joint and skin improvements with a favorable safety profile. Results were presented at the ACR Convergence 2026.